MARKET

CDXC

CDXC

ChromaDex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.41
-0.95
-7.08%
After Hours: 12.40 -0.01 -0.08% 19:17 03/02 EST
OPEN
13.19
PREV CLOSE
13.36
HIGH
13.84
LOW
12.37
VOLUME
2.90M
TURNOVER
--
52 WEEK HIGH
23.66
52 WEEK LOW
2.500
MARKET CAP
814.52M
P/E (TTM)
-32.9790
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ChromaDex Granted U.S. Patent Titled 'B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10934322.PN.&OS=PN/10934322&RS=PN/10934322
Benzinga · 11h ago
3 Penny Stocks That Went Big In 2021 So Far
Penny Stocks · 5d ago
IIPR, GME, CDXC and SOS among midday movers
Gainers: Pandion Therapeutics (PAND) +133%.GameStop (GME) +66%.ChromaDex (CDXC) +59%.Dynatronics (DYNT) +57%.Koss (KOSS) +54%.Stereotaxis (STXS) +33%.ASLAN Pharmaceuticals (ASLN) +29%.Socket Mobile (SCKT) +26%.AeroCentury (ACY) +24%.Brookdale Senior Living...
Seekingalpha · 5d ago
Pandion Therapeutics, Dynatronics leads healthcare gainers; U.S. Physical Therapy, CollPlant Biotechnologies among major losers
Gainers: Pandion Therapeutics (PAND) +132%, Dynatronics (DYNT) +68%, ChromaDex (CDXC) +30%, ASLAN Pharmaceuticals (ASLN) +28%, Brookdale Senior Living (BKD) +22%.Losers: U.S. Physical Therapy (USPH) -21%, CollPlant Biotechnologies (CLGN) -21%, Akebia Thera...
Seekingalpha · 5d ago
ChromaDex Shares Rally After COVID-19 Patients on Nutrient Recover Faster in Study
MT Newswires · 5d ago
8-K: ChromaDex Corp.
(EDGAR Online via COMTEX) -- 0001386570 false 0001386570 2021-02-23 2021-02-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
Gamma Oryzanol Market Research By Growth, Manufacturers, Regions, Type, Application and Forecast 2020 - 2027 by ARC
pune, India, Thu, 25 Feb 2021 00:26:18 / Comserve Inc. / -- Acumen Research and Consulting has announced the addition of the "Global Gamma Oryzanol Market :...
Comserve · 5d ago
BRIEF-New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery In Mild-To-Moderate Covid-19 Patients
reuters.com · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDXC. Analyze the recent business situations of ChromaDex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDXC stock price target is 7.90 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 16.56M
% Owned: 26.80%
Shares Outstanding: 65.63M
TypeInstitutionsShares
Increased
29
969.16K
New
25
-146.93K
Decreased
21
284.66K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Executive Director
Frank Jaksch
Chief Executive Officer/Director
Robert Fried
Chief Financial Officer
Kevin Farr
Senior Vice President
Megan Jordan
General Counsel/Secretary
Mark Friedman
Lead Director/Independent Director
Kurt Gustafson
Senior Director/IR Contact Officer
Brianna Gerber
Independent Director
Jeffrey Baxter
Independent Director
Stephen Block
Independent Director
Tony Lau
Independent Director
Steven Rubin
Independent Director
Wendy Yu
  • Dividends
  • Splits
  • Insider Activity
No Data
About CDXC
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.